Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Spectrum Pharmaceuticals to Present Data from Phase 2 Clinical Trial for Poziotinib at Upcoming Medical Conference

The oral presentation will take place on March 18, 2020 from 9:30 to 10:15 a.m. CET in Amsterdam. The abstract can be found here: poziotinib abstract.
Conference Call and Webcast
Spectrum’s management will host a webcast and conference call at 8 a.m. ET / 5 a.m. PT on March 18, 2020 to review the data and program strategy. The live call may be accessed by dialing [phone] for domestic callers and [phone] for international callers and entering the conference ID#:2059147. A live webcast of the call will be available from the Investors and Media section of the company’s website at http://investor.sppirx.com/events-and-presentations and will be archived there shortly after the live event.
http://investor.sppirx.com/news-releases/news-release-details/spectrum-pharmaceuticals-present-data-phase-2-clinical-trial

Looking forward to this IF they give us some worthwhile info such as why MDACC's data was so different than cohort 1. And what does that 17% CI mean. And we know there is a plan going forward but it would be good to know what the plan is and the timeline to fruition and if this delay will possibly impact getting AA, etc.